Motexafin GadoliniumCancer Treatment product candidate

Motexafin Gadolinium (MGd)

  • Is a first in class small molecule drug with a novel mechanism of action ClosecloseMechanism of ActionThe biologic and chemical explanation for how a drug works.
  • Belongs to a class of compound called texaphyrins and accumulates selectively in cancer cells
  • Is paramagnetic ClosecloseParamagneticA form of magnetism which occurs only in the presence of an externally applied magnetic field. Paramagnets do not retain any magnetizationand is detectable by MRI (magnetic resonance imaging ) , allowing the visualization of the drug in tumors

Motexafin Gadolinium Tumor Selectivity Detectable by MRI

Pre MGd After 1st Dose of MGd
    T1 weighted non-contrast MRI scans
  • Once inside the cell, MGd may induces apoptosis ClosecloseApoptosisA term meaning programmed cell death or cell suicide, usually involves an orderly interruption of cell functions resulting in cell death.by disrupting cellular metabolism ClosecloseCellular metabolismA set of chemical reactions that occur in living organisms in order to maintain life.within the cancer cell, increasing tumor ClosecloseTumorAn abnormal growth of cells that may be the result of cancer.oxygenation and inhibition of DNA ClosecloseDNADeoxyribonucleic acid (DNA) - A nucleic acid that contains the genetic instructions used in the development and functioning of all known living organisms and some viruses. The main role of DNA molecules is the long-term storage of information. DNA is often compared to a set of blueprints or a recipe, or a code, since it contains the instructions needed to construct other components of cells, such as proteins and RNA molecules.repair.

MGd in Brain Metastases

Motexafin Gadolinium has been evaluated in clinical trials involving over 1000 patients and has been found to be generally well tolerated with excellent safety profile.

Clinical Trial

Phase 1/2 Trial of MGd and Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme ClosecloseGlioblastoma multiformeA type of cancer that arises in the brain. (RTOG/NCI-sponsored trial)